Table 2.

Ferroptosis-related drugs are involved in the treatment of AKI to CKD.

Drugs	Animal models	Mice types	Cell types	Mechanisms	References
Liproxstatin-1	UUO	C57BL/6 mice	TEC, HK-2	Reduce lipid peroxidation	[103]
Ferrostatin-1	Cis-AKI	CD1 mice	HK-2	Reduce lipid peroxidation	[138]
Ferrostatin 16-86	IRI-AKI	C57BL/6 mice	Primary mouse renal tubules	Reduce lipid peroxidation	[125]
Vitamin E	IRI-AKI	C57BL/6 mice	RPTECs	Antioxidant	[139]
Vitamin K	IRI-AKI	C57BL/6 mice	RPTECs	Antioxidant	[41]
Paricalcitol	Cis-AKI	C57BL/6 mice	HK-2	Antioxidant	[131]
Irisin	IRI-AKI	C57BL/6 J mice	HK-2	Antioxidant	[140]
Tectorigenin	UUO	C57BL/6 mice	RPTECs	Antioxidant	[128]
Isoliquirtigenin	LPS-AKI	C57BL/6 mice	HK-2	Antioxidant	[141]
Melatonin	IRI-AKI, FA-AKI	C57BL/6 J mice	TEC	Antioxidant	[142]
Quercetin	IRI-AKI, FA-AKI	C57BL/6 J mice	NRK-52E, HK-2	Antioxidant	[143]
Deferoxamine	CKD	Sprague‒Dawley rat	–	Iron chelator	[132]
Nobiletin	UUO	C57BL/6 J mice	–	Antioxidant; anti-inflammatory	[129]

UUO unilateral ureteral obstruction, Cis-AKI cisplatin-induced acute kidney injury, RPTECs primary renal proximal tubular epithelial cells, MH-ARF myohemoglobinuric acute renal failure.